Compare GIII & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | NTLA |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2006 | 2016 |
| Metric | GIII | NTLA |
|---|---|---|
| Price | $30.77 | $10.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | ★ $34.75 | $22.78 |
| AVG Volume (30 Days) | 330.0K | ★ 4.3M |
| Earning Date | 12-08-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $2,957,012,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.17 | $174.74 |
| P/E Ratio | $15.94 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $24.61 | $8.09 |
| 52 Week High | $37.54 | $18.48 |
| Indicator | GIII | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 42.91 |
| Support Level | $26.69 | N/A |
| Resistance Level | $32.80 | $13.59 |
| Average True Range (ATR) | 1.06 | 0.78 |
| MACD | -0.17 | -0.16 |
| Stochastic Oscillator | 8.43 | 34.39 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.